Pediatrix Medical Group, Inc.
NYSE:MDMedical - Care Facilities
-$0.48 today
- Market cap
- $2.41B
- Beta
- 0.70
- P/E (TTM)
- 11.0
- EPS (TTM)
- $2.10
Volume 0.64M
Average 0.82M
MD Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Pediatrix Medical Group, Inc.NYSE: MD
Depreciation & Amortization · Q3 FY2026 · quarter ended Sep 2026
Depreciation & amortization growth accelerates
Q3 FY2026 depreciation & amortization of $6.24M rose 12.5% year over year, ahead of the +3.1% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 8.0% from the prior quarter. Over 3 fiscal years it compounded at -15.1% a year.
Context
- Depreciation & amortization amounted to 1.1% of revenue in FY2025, down 0.5 pp from a year earlier.
- Depreciation & amortization increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +12.5% holds above the trailing-twelve-month pace of +3.1%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 21.83M USD
- Year-over-year change
- -32.3%
- 4-year CAGR
- -9.2%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 21.83M | -32.3% |
| FY2024 | 2024-12-31 | 32.23M | -10.9% |
| FY2023 | 2023-12-31 | 36.17M | +1.5% |
| FY2022 | 2022-12-31 | 35.64M | +10.9% |
| FY2021 | 2021-12-31 | 32.15M | — |
Depreciation & Amortization vs competitors
How MD compares with its peers on the latest reported figures
- MD's LTM Sep 2026 depreciation & amortization of $23.78M is the 9th largest of the 11 companies compared; the peer median is $54.47M.
- Its year-over-year change of +3.1% is the 8th highest of 11, against a peer median of +10.2%.
- Depreciation & amortization amounts to 1.2% of revenue for MD, versus a peer median of 2.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $344M | +0.6% | +19.4% | 5.6% | |
| LTM Sep 2026 | $201.74M | +10.2% | +17.1% | 5.9% | |
ARDTArdent Health Partners, LLC | LTM Mar 2026 | $162.49M | +10.4% | +4.1% | 2.5% |
| LTM Mar 2026 | $140.3M | -24.0% | -12.0% | 2.5% | |
| LTM Jun 2026 | $54.56M | -5.2% | -7.5% | 3.4% | |
| LTM Mar 2026 | $54.38M | +83.2% | +37.6% | 1.5% | |
| LTM Sep 2026 | $49.13M | +10.2% | +3.5% | 3.1% | |
| LTM Oct 2026 | $30.08M | +6.5% | -10.1% | 1.1% | |
| LTM Sep 2026 | $23.78M | +3.1% | -15.1% | 1.2% | |
GRDNGuardian Pharmacy Services, Inc. | LTM Jun 2026 | $23.36M | +11.8% | +10.5% | 1.6% |
| LTM Jun 2026 | $16.71M | +15.1% | +5.3% | 1.1% | |
| Peer median (excluding MD) | $54.47M | +10.2% | +4.7% | 2.5% | |
Competitors are the stored peer set for MD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 108.01M | 62.57M | (60.41M) | (99.07M) | 165.39M |
| Depreciation & Amortization | 32.15M | 35.64M | 36.17M | 32.23M | 21.83M |
| Deferred Income Tax | (31.24M) | (22.77M) | 3.24M | (2.13M) | 52.19M |
| Stock-Based Compensation | 18.97M | 16.13M | 12.32M | 11.87M | 18.05M |
| Change in Working Capital | (23.36M) | 31.83M | (11.63M) | 88.24M | 41.83M |
| Accounts Receivables | (72.73M) | (5.54M) | 26.28M | 10.29M | 30.56M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 21.33M | 420K | (11.92M) | 51.14M | 28.33M |
| Other Working Capital | 28.05M | 36.95M | (25.98M) | 26.81M | (17.06M) |
| Other Non-Cash Items | (27.8M) | 43.55M | 157.63M | 175.44M | (28.18M) |
| Operating Cash Flow | 76.74M | 166.94M | 137.33M | 206.57M | 271.09M |
| Capital Expenditures | (32.25M) | (29.71M) | (33.33M) | (22.02M) | (18.46M) |
| Acquisitions (Net) | (29.93M) | (28.17M) | (6.67M) | (8.17M) | 6.8M |
| Purchases of Investments | (35.05M) | (17.35M) | (31.89M) | (64.55M) | (29.85M) |
| Sales of Investments | 16.5M | 16.89M | 22.91M | 52.49M | 26.67M |
| Other Investing Activities | 27.66M | 1.38M | 807K | 6.84M | (3.47M) |
| Investing Cash Flow | (53.07M) | (56.95M) | (48.18M) | (35.41M) | (18.3M) |
| Debt Repayment | (762.66M) | (405.17M) | (19.12M) | (15.39M) | (20.75M) |
| Common Stock Issued | 6.85M | 5.4M | 4.91M | 3.64M | 3.18M |
| Common Stock Repurchased | (4.72M) | (88.51M) | (919K) | (1.7M) | (86.68M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 407K | 732K | (10.59M) | (1.03M) | (3.25M) |
| Financing Cash Flow | (760.12M) | (487.55M) | (25.72M) | (14.49M) | (107.49M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (736.45M) | (377.57M) | 63.43M | 156.68M | 145.3M |
| Free Cash Flow | 44.49M | 137.23M | 104M | 184.55M | 252.63M |
Pediatrix Medical Group, Inc.
NYSE:MD
Intrinsic Alpha fair value
Locked
Current Price
$30.84
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.